9 August 2021 
The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The evitria Group is a global leader in the field of transient CHO cell antibody expression with an international customer portfolio of leading biopharma companies in therapeutic and diagnostic antibody research. The transaction was completed on August 5, 2021.
VISCHER advised the sellers on this transaction with a team led by Dr. Jürg Luginbühl (Corporate/M&A) with Marc Ph. Prinz (Partner, Employment), Dr. Adrian Dörig (Partner, Banking/Finance), Dr. Stefan Kohler (Partner, IP/Regulatory), Christian Schneiter (Banking/Finance), Sebastian Weber (Corporate/M&A), Flavio Langenegger (Corporate/M&A) and Gordana Nisevic (Corporate/M&A).